← All trials
NCT05952076
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 3, 2023
- Primary completion
- Mar 16, 2024
- Completion date
- Apr 16, 2024
- First posted
- Jul 19, 2023
- Last posted
- Dec 6, 2023
- Enrollment
- 396
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Bill and Melinda Gates FoundationLead sponsor
- Bill and Melinda Gates FoundationStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.